Chiasma, Inc.

UEI
NMC8LJZXNTZ6
CAGE
8Q9K1
Primary NAICS
325412 Pharmaceutical Preparation Manufacturing
SAM.gov registration
Expired

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract vehicles

Similar vendors

About the company

Chiasma, Inc., doing business as Chiasma, is a commercial biopharmaceutical company focused on developing and commercializing oral therapies for patients suffering from rare and serious chronic diseases. The company's lead product is MYCAPSSA, the first oral somatostatin analog approved by the FDA for the long-term maintenance treatment of acromegaly in adults.

Chiasma, Inc. holds multiple federal contract IDVs with the Department of Veterans Affairs (VA) to provide MYCAPSSA and other pharmaceuticals and drugs. In November 2021, the VA National Acquisition Center awarded Chiasma a single-award Blanket Purchase Agreement (BPA) under the Pharmaceuticals and Drugs GSA Schedule, valued at up to $250,000, to facilitate ordering of MYCAPSSA for acromegaly treatment at VA medical centers through October 2022. Additionally, in July 2021, Chiasma received a multiple-award Federal Supply Schedule contract from VA Integrated Service Network 12, with a $6.3 million ceiling over 5 years, for procuring pharmaceuticals and drugs including MYCAPSSA. Prior to this, Chiasma had an interim agreement under the same VA schedule, awarded in January 2021 with a $25,000 value.

Quick answers

Is Chiasma, Inc. registered in SAM.gov?

Chiasma, Inc.'s SAM.gov registration expired on July 21, 2022.

Which contract vehicles does Chiasma, Inc. hold?

Chiasma, Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.

On GovTribe

See Chiasma, Inc.'s full federal record

  • IDV awards
  • Contract vehicles
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors